<DOC>
	<DOC>NCT01604746</DOC>
	<brief_summary>The purpose of this study is to verify the long-term safety of a 2.5 µg, adjuvanted (aluminium hydroxide) dose of Ross River Virus (RRV) vaccine.</brief_summary>
	<brief_title>Additional 6-Month Safety Follow-up After Completion of Precursor Study 880801</brief_title>
	<detailed_description />
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects who participated in precursor Study 880801 and meet all of the following criteria: Subject received 3 RRV vaccinations in Study 880801 Subject has completed Visit 6 in Study 880801 Subject and, if applicable, subject´s parent(s)/legal guardian(s), understand the nature of the study and its procedures, agree to its provisions and provide written informed consent prior to study entry Subject provides written assent according to his/her age, if applicable Subject has participated in another clinical study other than Study 880801 involving an investigational product (IP) or investigational device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>